Sinclair IS Pharma shares drop despite strong end to the year

Shares in Sinclair IS Pharma moved lower after the company reported a strong second half.

Sinclair IS Pharma shares were down by 2.19% to 44.75p at 16:18 BST.

The cosmetic treatment provider, which is in talks to be fully or partially sold, said like-for-like growth for the year was 8%, compared with 4% the year before.

Sinclair said this growth showed the impact of its aesthetics portfolio, which made up 47% of reported revenue, at £35.8m.

Full year revenues were up by 19% to £75.9m, compared to £63.6m last year.

Sinclair ended the year with cash of £12.7m and net debt of £42.2m.

Chief executive Chris Spooner said the second half had made up for a disappointing first half which was poorer due to delays and teething problems with new products.